Weifa

Weifa ASA

Type	Allmennaksjeselskap
Traded as	OSE: WEIFA
Industry	Pharmaceutical
Founded	1940
Headquarters	Oslo, Norway
Revenue	500mill NOK (2012)
Number of employees	180
Website	www.weifa.no

Weifa^[1] is a Norwegian pharmaceutical company headquartered in Oslo with production facilities in Kragerø.

Weifa is one of the world’s largest producers of Metformin hydrochloride and a leading producer of alkaloid opiates. Production facilities follow GMP standards.

History

Weifa was founded by pharmacist Olaf Weider in 1940.^[2]

Therapeutic areas

Weifa focuses on three therapeutic areas:

1. Pain management
2. Diabetes management
3. Food supplements

Products

• bra!: Evening primrose oil.
• Bronkyl: Expectorant effervescent tablet.^[3]
• Dexyl: Nasal spray.^[4]
• Fanalgin: Pain reliever and fever reducer with an addition of caffeine.^[5]
• Ferromax: Iron supplement.^[6]
• Fluormax: Fluorine supplements.^[7]
• Ibux: A brand name for ibuprofen.
• Ibux Gel: A gel version of Ibux.^[8]
• Nazamér: Salt water spray.^[9]
• Nazaren: Nasal spray.Salt water spray.^[10]
• Paracet: A brand name for paracetamol.^[11]
• Paracetduo: Similar to Paracet with the addition of caffeine for increased pain relief.^[12]
• Proxan: Brand name for naproxen.^[13]
• Pyrivir: Relieves symptoms of cold sores.^[14]
• Samin: Symptom relief in patients with Osteoarthritis.
• Tigerbalsam: Heat rub.^[15]
• Tussin: Cough medicine.^[16]
• Weifa-C Nypeekstrakt: Vitamin C from rose hip extract.
• Weifa C-vitamin brusetabletter: Vitamin C effervescent tablets.
• Weifa Kalsium: Calcium supplements.

Active ingredients

• Codeine: Used in pain relievers and cough medicine.^[17]
• Metformin: Used in first-line treatment of diabetes mellitus type 2.^[18]
• Pholcodine: Used in cough medicine.^[17]

Development

With a total of over 250 employees, Weifa is today generating an annual turnover of approximately €40 million (35% of the turnover is achieved internationally). Weifa bases its development on 3 criteria:

1. International expansion
2. Expertise in pharmaceuticals and fine chemicals
3. Partnership agreements

Norway

Weifa has market leadership in pain management products for the Norwegian market, with a portfolio of branded products that includes established brand names such as the Ibux tablets, Paracet tablets and Paralgin Forte tablets. Branded products accounts for approximately 70% of net sales.

Export

Weifa’s leading export markets are Germany and United Kingdom. Besides these two essential export markets, Weifa has a long-standing presence in all the main countries of the European Union, in Eastern Europe, in Africa, in North America, in South America and in Asia.

References

1. http://www.weifa.com
2. "Kjøper Weifa for 1,17 milliarder". Dagens Næringsliv. 17 June 2014. Archived from the original on 11 September 2014.
3. "Bronkyl". Felleskatalogen. Archived from the original on 11 September 2014.
4. "Dexyl". Felleskatalogen. Archived from the original on 11 September 2014.
5. "Fanalgin". Felleskatalogen. Archived from the original on 11 September 2014.
6. "Ferromax". Felleskatalogen. Archived from the original on 6 October 2014.
7. "Fluormax". Weifa. Archived from the original on 6 October 2014.
8. "Ibux Gel". Legemiddelsiden.no. Archived from the original on 11 September 2014.
9. "Nazamér". Weifa. Archived from the original on 11 September 2014.
10. "Nazaren". Felleskatalogen. Archived from the original on 11 September 2014.
11. "Paracet". Felleskatalogen. Archived from the original on 11 September 2014.
12. "Paracetduo". Felleskatalogen. Archived from the original on 11 September 2014.
13. "Proxan". Felleskatalogen. Archived from the original on 11 September 2014.
14. "Pyrivir". Weifa. Archived from the original on 11 September 2014.
15. "Tigerbalsam". Weifa. Archived from the original on 11 September 2014.
16. "Tussin". Felleskatalogen. Archived from the original on 11 September 2014.
17. "Weifa - Opioids". Weifa. Archived from the original on 15 September 2014.
18. "Weifa - Metformin". Weifa. Archived from the original on 15 September 2014.